AXIOS October 6, 2023
Emily Peck

As Ozempic and similar weight loss drugs become more popular, Americans might start buying less food, particularly high-calorie snacks and fast food.

Why it matters: That could radically reshape the food industry, and investors and food industry executives are starting to pay attention.

Driving the news: Earlier this week, Walmart’s U.S. CEO told Bloomberg that customers taking Ozempic buy less food. (Walmart mined its own pharmacy and grocery data to pinpoint customer buying patterns, per Bloomberg.)

  • “We definitely do see a slight change compared to the total population, we do see a slight pullback,” John Furner said. “Just less units, slightly less calories.” But he added that it’s still early days for Ozempic.
  • The drug itself has boosted sales...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Retailer
Related Articles:
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Mark Cuban's 2025 plans
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025

Share This Article